Agilent Technologies, Inc. (A) is listed on NYSE and operates in the Medical - Diagnostics & Research industry (Healthcare sector).
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbid...
| Rating | Analysts |
|---|---|
| Strong Buy | 1 |
| Buy | 28 |
| Hold | 8 |
| Sell | 1 |
| Strong Sell | 0 |
Agilent Technologies, Inc., established in 1999 and headquartered in Santa Clara, California, delivers solutions for the life sciences, diagnostics, and applied chemical markets globally. The company operates through three main segments. The Life Sciences and Applied Markets segment provides chromatography and spectrometry systems, cell analysis tools, laboratory software, and automation systems. The Diagnostics and Genomics segment offers DNA analysis arrays, next-generation sequencing tools, genetic data management software, immunohistochemistry, and various staining products. It also supplies reagents for turbidimetry and flow cytometry, and develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment focuses on laboratory instrument supplies, sample preparation products, and custom chemistries, alongside offering services such as startup, operational support, training, compliance, and asset management. Agilent markets its products through direct sales, distributors, resellers, manufacturer's representatives, and online platforms.
Over the past three fiscal years, the company has demonstrated a mixed financial performance. Revenue showed an inconsistent trend, with a modest CAGR of 0.8%, starting at $6.83 billion in 2023 and ending at $6.95 billion in 2025. Despite the revenue fluctuations, earnings per share (EPS) consistently increased at a CAGR of 4.4%, rising from $4.19 to $4.57, indicating effective cost management and operational efficiency. Gross and operating margins experienced slight expansions, with gross margin improving by 1.7 percentage points to 52.4% and operating margin increasing by 1.5 percentage points to 21.3%, reflecting some degree of operating leverage. However, cash flow generation faced challenges, as both operating cash flow (OCF) and free cash flow (FCF) consistently decreased, with FCF dropping from $1.47 billion to $1.15 billion, resulting in a declining FCF margin from 21.6% to 16.6%. The company's net debt position increased significantly, from $1.15 billion to $1.57 billion, suggesting higher leverage. Despite these challenges, the company maintained strong cash conversion, with a cash conversion ratio (CCR) of 3.6, indicating that earnings are well-supported by cash. Additionally, the company reduced its share count by 4.1%, which helped enhance per-share value for shareholders. Overall, while the company has managed to improve profitability and maintain strong earnings quality, the decline in cash flows and increased leverage are areas that may require attention.
Agilent Technologies has experienced significant developments recently, primarily centered around its financial performance and analyst ratings. Following its latest earnings report, Agilent's stock has declined by 6.2%, as noted by Zacks Investment Research on March 27, 2026. Analysts have adjusted their ratings, with TD Cowen and Barclays lowering their price targets to $170 and $165, respectively, while the average 12-month price objective remains at $161, maintaining a "Moderate Buy" consensus. In terms of institutional activity, Boston Trust Walden Corp and Nordea Investment Management AB have sold 21,880 and 106,321 shares, respectively, while Assetmark Inc. acquired 12,984 shares, indicating mixed sentiment among institutional investors. On the product front, Agilent announced the BioTek Cytation 9 Cell Imaging Multimode Reader on April 1, 2026, expanding its product offerings. Additionally, Agilent resolved litigation with Axion BioSystems and showcased cancer research solutions at AACR 2026. These developments reflect a period of strategic adjustments and market reactions for Agilent Technologies.
Agilent Technologies operates in the life sciences, diagnostics, and applied chemical markets. The industry is currently experiencing a dynamic environment with both opportunities and challenges. Key macro trends include the reshoring of pharmaceutical and semiconductor manufacturing, increased demand for GLP-1 and LC/GC instrument replacements, and evolving EU regulations impacting PFAS workflows. Management identifies tailwinds such as strong demand in pharma and semiconductor sectors, while headwinds include tariff uncertainties and softness in academia and government funding, particularly in the U.S. Over the calls, the industry context has remained largely consistent, with ongoing emphasis on innovation and customer intimacy as strategic differentiators.
Agilent's recent performance was shaped by several strategic initiatives and external factors. In Q1 2026, the company reported $1.8 billion in revenue, growing 4.4% on a core basis, despite a $10 million impact from a U.S. winter storm. The storm affected logistics, but most revenue was recovered shortly after. Management expressed satisfaction with the execution of their Ignite Operating System, which contributed to margin improvements and operational efficiencies. Product innovations like the Altura column and Pro iQ LC/MS saw strong uptake, driving growth in biopharma and diagnostics. However, there were concerns about softness in academia and government funding, impacting cell analysis and genomics. The narrative between calls showed consistent growth in key markets like pharma and CAM, with ongoing challenges in academia and government sectors.
Agilent's strategy focuses on leveraging its Ignite Operating System to drive growth and operational excellence. Investments are being made in innovation, digital capabilities, and strategic capacity expansion, particularly in the specialty CDMO segment. Management claims competitive advantages in customer intimacy and a robust innovation pipeline, supported by recent product launches like the Altura columns and Pro iQ LC/MS. Risks include tariff uncertainties and potential softness in academia and government funding. Analysts questioned the impact of tariffs and the company's ability to maintain growth amid these challenges. The tension in the thesis lies in balancing innovation and market expansion with external economic pressures. Long-term investors might be excited by the company's strong market position and innovation pipeline, but should be cautious about geopolitical and regulatory risks.
Between the Q4 2025 and Q1 2026 calls, Agilent demonstrated consistent execution on its strategic initiatives. Management delivered on commitments to grow core revenue and improve margins, despite the weather-related disruption. The Ignite Operating System continued to drive efficiencies and margin improvements as promised. Guidance set in Q4 2025 for revenue and EPS was met in Q1 2026, with adjustments for the storm impact. Management remained vocal about their strategic priorities and did not go silent on previously emphasized topics, indicating a steady focus on execution and growth.
- Monitor Q2 2026 revenue guidance of $1.79 to $1.82 billion, with core growth of 4% to 5.5%.
- Check EPS guidance for Q2 2026, expected between $1.39 and $1.42, representing 6% to 8% growth.
- Watch for continued progress in the Ignite Operating System's impact on margin expansion, aiming for 75 basis points improvement for FY 2026.
- Observe developments in the specialty CDMO segment, particularly the ramp-up of new capacity and its impact on growth.
- Assess the impact of tariff changes and Agilent's mitigation strategies on operating margins.
- Evaluate the recovery in academia and government funding, especially in the U.S., and its influence on the cell analysis and genomics segments.